Switch theme
Sign up to access all valuation multiples
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
2011
13
LTM Revenue $0.6M
LTM EBITDA -$43.8M
-$34.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
VYNE Therapeutics has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of -$43.8M.
In the most recent fiscal year, VYNE Therapeutics achieved revenue of $0.5M and an EBITDA of -$43.6M.
VYNE Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See VYNE Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$43.8M | XXX | -$43.6M | XXX | XXX | XXX |
| EBITDA Margin | -7503% | XXX | -8709% | XXX | XXX | XXX |
| EBIT | -$42.5M | XXX | -$43.6M | XXX | XXX | XXX |
| EBIT Margin | -7286% | XXX | -8710% | XXX | XXX | XXX |
| Net Profit | -$39.6M | XXX | -$39.8M | XXX | XXX | XXX |
| Net Margin | -6794% | XXX | -7951% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, VYNE Therapeutics's stock price is $1.
VYNE Therapeutics has current market cap of $15.8M, and EV of -$34.4M.
See VYNE Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$34.4M | $15.8M | XXX | XXX | XXX | XXX | $-0.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, VYNE Therapeutics has market cap of $15.8M and EV of -$34.4M.
VYNE Therapeutics's trades at -68.6x EV/Revenue multiple, and 0.8x EV/EBITDA.
Equity research analysts estimate VYNE Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VYNE Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for VYNE Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.8M | XXX | $15.8M | XXX | XXX | XXX |
| EV (current) | -$34.4M | XXX | -$34.4M | XXX | XXX | XXX |
| EV/Revenue | -58.9x | XXX | -68.6x | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBIT | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/Gross Profit | -58.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVYNE Therapeutics's last 12 month revenue growth is 2%
VYNE Therapeutics's revenue per employee in the last FY averaged $39K, while opex per employee averaged $3.4M for the same period.
VYNE Therapeutics's rule of 40 is -6898% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
VYNE Therapeutics's rule of X is -7497% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for VYNE Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -7503% | XXX | -8709% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | -6898% | XXX | -8707% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -7497% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $39K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6177% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8810% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VYNE Therapeutics acquired XXX companies to date.
Last acquisition by VYNE Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . VYNE Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was VYNE Therapeutics founded? | VYNE Therapeutics was founded in 2011. |
| Where is VYNE Therapeutics headquartered? | VYNE Therapeutics is headquartered in United States of America. |
| How many employees does VYNE Therapeutics have? | As of today, VYNE Therapeutics has 13 employees. |
| Who is the CEO of VYNE Therapeutics? | VYNE Therapeutics's CEO is Mr. David Domzalski. |
| Is VYNE Therapeutics publicy listed? | Yes, VYNE Therapeutics is a public company listed on NAS. |
| What is the stock symbol of VYNE Therapeutics? | VYNE Therapeutics trades under VYNE ticker. |
| When did VYNE Therapeutics go public? | VYNE Therapeutics went public in 2018. |
| Who are competitors of VYNE Therapeutics? | Similar companies to VYNE Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of VYNE Therapeutics? | VYNE Therapeutics's current market cap is $15.8M |
| What is the current revenue of VYNE Therapeutics? | VYNE Therapeutics's last 12 months revenue is $0.6M. |
| What is the current revenue growth of VYNE Therapeutics? | VYNE Therapeutics revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of VYNE Therapeutics? | Current revenue multiple of VYNE Therapeutics is -58.9x. |
| Is VYNE Therapeutics profitable? | Yes, VYNE Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of VYNE Therapeutics? | VYNE Therapeutics's last 12 months EBITDA is -$43.8M. |
| What is VYNE Therapeutics's EBITDA margin? | VYNE Therapeutics's last 12 months EBITDA margin is -7503%. |
| What is the current EV/EBITDA multiple of VYNE Therapeutics? | Current EBITDA multiple of VYNE Therapeutics is 0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
